135 related articles for article (PubMed ID: 29425861)
21. Cyclosporin A affects the bioavailability of ginkgolic acids via inhibition of P-gp and BCRP.
Li L; Yao QQ; Xu SY; Hu HH; Shen Q; Tian Y; Pan LY; Zhou H; Jiang HD; Lu C; Yu LS; Zeng S
Eur J Pharm Biopharm; 2014 Nov; 88(3):759-67. PubMed ID: 24980806
[TBL] [Abstract][Full Text] [Related]
22. P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib.
Chen Y; Agarwal S; Shaik NM; Chen C; Yang Z; Elmquist WF
J Pharmacol Exp Ther; 2009 Sep; 330(3):956-63. PubMed ID: 19491323
[TBL] [Abstract][Full Text] [Related]
23. Functions of the breast cancer resistance protein (BCRP/ABCG2) in chemotherapy.
Noguchi K; Katayama K; Mitsuhashi J; Sugimoto Y
Adv Drug Deliv Rev; 2009 Jan; 61(1):26-33. PubMed ID: 19111841
[TBL] [Abstract][Full Text] [Related]
24. A new mechanism for increasing the oral bioavailability of scutellarin with Cremophor EL: Activation of MRP3 with concurrent inhibition of MRP2 and BCRP.
Xiao L; Yi T; Chen M; Lam CW; Zhou H
Eur J Pharm Sci; 2016 Oct; 93():456-67. PubMed ID: 27586020
[TBL] [Abstract][Full Text] [Related]
25. P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan.
de Vries NA; Zhao J; Kroon E; Buckle T; Beijnen JH; van Tellingen O
Clin Cancer Res; 2007 Nov; 13(21):6440-9. PubMed ID: 17975156
[TBL] [Abstract][Full Text] [Related]
26. Investigation of MDR1-overexpressing cell lines to derive a quantitative prediction approach for brain disposition using in vitro efflux activities.
Sato S; Tohyama K; Kosugi Y
Eur J Pharm Sci; 2020 Jan; 142():105119. PubMed ID: 31682973
[TBL] [Abstract][Full Text] [Related]
27. Aristolochic acid I is a substrate of BCRP but not P-glycoprotein or MRP2.
Ma L; Qin Y; Shen Z; Bi H; Hu H; Huang M; Zhou H; Yu L; Jiang H; Zeng S
J Ethnopharmacol; 2015 Aug; 172():430-5. PubMed ID: 26183576
[TBL] [Abstract][Full Text] [Related]
28. Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein.
Allen JD; Van Dort SC; Buitelaar M; van Tellingen O; Schinkel AH
Cancer Res; 2003 Mar; 63(6):1339-44. PubMed ID: 12649196
[TBL] [Abstract][Full Text] [Related]
29. Enhanced brain accumulation of pazopanib by modulating P-gp and Bcrp1 mediated efflux with canertinib or erlotinib.
Minocha M; Khurana V; Qin B; Pal D; Mitra AK
Int J Pharm; 2012 Oct; 436(1-2):127-34. PubMed ID: 22688250
[TBL] [Abstract][Full Text] [Related]
30. Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP.
de Vries NA; Buckle T; Zhao J; Beijnen JH; Schellens JH; van Tellingen O
Invest New Drugs; 2012 Apr; 30(2):443-9. PubMed ID: 20963470
[TBL] [Abstract][Full Text] [Related]
31. No Effect of Levothyroxine and Levothyroxine-Induced Subclinical Thyrotoxicosis on the Pharmacokinetics of Sorafenib in Healthy Male Subjects.
Huang F; Ajavon A; Huang E; Lettieri J; Liu R; Peña C; Berse M
Thyroid; 2017 Sep; 27(9):1118-1127. PubMed ID: 28741453
[TBL] [Abstract][Full Text] [Related]
32. P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387.
Durmus S; Xu N; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
Pharmacol Res; 2013 Oct; 76():9-16. PubMed ID: 23827160
[TBL] [Abstract][Full Text] [Related]
33. The gut microbiota ellagic acid-derived metabolite urolithin A and its sulfate conjugate are substrates for the drug efflux transporter breast cancer resistance protein (ABCG2/BCRP).
González-Sarrías A; Miguel V; Merino G; Lucas R; Morales JC; Tomás-Barberán F; Alvarez AI; Espín JC
J Agric Food Chem; 2013 May; 61(18):4352-9. PubMed ID: 23586460
[TBL] [Abstract][Full Text] [Related]
34. Insight into the cooperation of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) at the blood-brain barrier: a case study examining sorafenib efflux clearance.
Agarwal S; Elmquist WF
Mol Pharm; 2012 Mar; 9(3):678-84. PubMed ID: 22335402
[TBL] [Abstract][Full Text] [Related]
35. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.
Kodaira H; Kusuhara H; Ushiki J; Fuse E; Sugiyama Y
J Pharmacol Exp Ther; 2010 Jun; 333(3):788-96. PubMed ID: 20304939
[TBL] [Abstract][Full Text] [Related]
36. The effects of triptolide on the pharmacokinetics of sorafenib in rats and its potential mechanism.
Wang X; Zhang X; Liu F; Wang M; Qin S
Pharm Biol; 2017 Dec; 55(1):1863-1867. PubMed ID: 28614959
[TBL] [Abstract][Full Text] [Related]
37. Neochamaejasmin B increases the bioavailability of chamaechromone coexisting in Stellera chamaejasme L. via inhibition of MRP2 and BCRP.
Pan L; Zeng K; Wang X; Bi H; Hu H; Huang M; Lou Y; Zeng S
Int J Pharm; 2015 Dec; 496(2):440-7. PubMed ID: 26475967
[TBL] [Abstract][Full Text] [Related]
38. In vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: implications for disposition and drug interactions.
Reyner EL; Sevidal S; West MA; Clouser-Roche A; Freiwald S; Fenner K; Ullah M; Lee CA; Smith BJ
Drug Metab Dispos; 2013 Aug; 41(8):1575-83. PubMed ID: 23729661
[TBL] [Abstract][Full Text] [Related]
39. The effect of Bcrp1 (Abcg2) on the in vivo pharmacokinetics and brain penetration of imatinib mesylate (Gleevec): implications for the use of breast cancer resistance protein and P-glycoprotein inhibitors to enable the brain penetration of imatinib in patients.
Breedveld P; Pluim D; Cipriani G; Wielinga P; van Tellingen O; Schinkel AH; Schellens JH
Cancer Res; 2005 Apr; 65(7):2577-82. PubMed ID: 15805252
[TBL] [Abstract][Full Text] [Related]
40. Brain Distribution of a Novel MEK Inhibitor E6201: Implications in the Treatment of Melanoma Brain Metastases.
Gampa G; Kim M; Cook-Rostie N; Laramy JK; Sarkaria JN; Paradiso L; DePalatis L; Elmquist WF
Drug Metab Dispos; 2018 May; 46(5):658-666. PubMed ID: 29437873
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]